Subcutaneous Drug Delivery A Route to Increased Safety, Patient Satisfaction, and Reduced Costs

被引:51
作者
Dychter, Samuel S. [1 ]
Gold, David A. [1 ]
Haller, Michael F. [2 ]
机构
[1] Halozyme Therapeut Inc, 11388 Sorrento Valley Rd, San Diego, CA 92121 USA
[2] Anaphore, La Jolla, CA USA
关键词
D O I
10.1097/NAN.0b013e31824d2271
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The subcutaneous (SC) route of administration is generally preferred over intravenous administration because it enables at-home injection, improves quality of life, and reduces health care costs. In general, a volume of no greater than 1 to 2 mL is injected SC; however, for high-dose agents with limited solubility, such as monoclonal antibodies, larger volumes must be administered, which requires divided doses, smaller volumes, or more frequent dose administration. Therapeutics are being formulated with an enzyme, recombinant human hyaluronidase, to enhance the dispersion and absorption of SC administered therapeutics by transiently depolymerizing hyaluronan, a major component of the interstitial matrix.
引用
收藏
页码:154 / 160
页数:7
相关论文
共 44 条
[21]  
Feldmann H, 2000, LARYNGO RHINO OTOL, V79, P239
[22]   Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration [J].
Frost, Gregory I. .
EXPERT OPINION ON DRUG DELIVERY, 2007, 4 (04) :427-440
[23]   Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home [J].
Gardulf, A ;
Nicolay, U ;
Asensio, O ;
Bernatowska, E ;
Böck, A ;
Costa-Carvalho, BT ;
Granert, C ;
Haag, S ;
Hernández, D ;
Kiessling, P ;
Kus, J ;
Matamoros, N ;
Niehues, T ;
Schmidt, S ;
Schulze, I ;
Borte, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (04) :936-942
[24]   Immunoglobulin treatment for primary antibody deficiencies - Advantages of the subcutaneous route [J].
Gardulf, Ann .
BIODRUGS, 2007, 21 (02) :105-116
[25]  
Gilbert D, 2005, HEMATOL ONCOL NE DEC, P25
[26]   Challenges for the oral delivery of macromolecules [J].
Goldberg, M ;
Gomez-Orellana, I .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) :289-295
[27]  
GOOD RA, 1991, CANCER, V68, P1415, DOI 10.1002/1097-0142(19910915)68:6+<1415::AID-CNCR2820681402>3.0.CO
[28]  
2-0
[29]  
Haller MF, 2005, DRUG DELIVERY TECHNO, V5, P40
[30]  
Haller MR, 2007, PHARM TECH, V10, P861